



Reconstruction of the Aortic Valve and Root: A Practical Approach

September 7-9-2022 Homburg/Saar, Germany

Reimplantation is the best root repair


Gebrine El Khoury, MD

Department of Cardiothoracic and Vascular Surgery
Cliniques Universitaires St-Luc, IREC, UCL, Brussels, Belgium




The origin of valve sparing root replacement operations

Remodeling technique (1983)




Sir M. Yacoub



Reimplantation technique (1992)





Prof. T. David






VSRR was developed to treat aortic root aneurism in TAV !

Root aneurism/no AI



Root aneurism + AI




OK

No?

And the debate started...

Remodeling



- Faster
- Less root dissection
- Only 1 suture line

Reimplantation




- More hemostatic
- More reliable
- Better Stabilisation in Marfan

≠


No long term outcomes !

Several modifications proposed


David's Operations (1992-2001)



(Reimplantation
in straight tube)



(= Remodeling)




(= Remodeling
+ partial external ring)



(Reimplantation with neosinuses)

Kari F.A. Circ 2013



VSRR: Why we do it?

Hospital mortality


12% AAD	• 1% (4/371 pts Reimpl. & Remod.)	T. David JTCVS 2014
8% AAD	• 2% (6/747 pts Remodeling)	H-J Schäfers EJCTS 2015
10% AAD	• 2% (4777 pts Metanalysis)	B. Arabkhani ATS 2015
Elective	• 0.3% (1/381 pts Reimplantation)	G. El Khoury, updated series 2000 – 2015
6% AAD	• 0.7% (1/146 Marfan Reimpl. & remod.)	T. David JACC 2015
4% AAD	• 0% (0/98 Marfan Reimpl. & remod.)	J. Price JTCVS 2016

1. SAFE !

VSRR: Why we do it?


Freedom from Reoperation

Reimpl. & Remod.




T. David JTCVS 2014

Remodeling



H-J Schafers EJCTS 2015

Reimplantation



S. Mastrobuoni STSA 2014

2. Durable !

VSRR: Why we do it?

Results

VSRR

Pooled Late Outcome Events	LOR + 95% CI
Late mortality	1.53 (1.19–1.96)
Reoperation on aortic valve	1.32 (1.0–1.74)
Hemorrhage	0.23 (0.13–0.42)
Thromboembolism	0.41 (0.22–0.77)
Endocarditis	0.23 (0.11–0.51)
MAVRE	1.66 (1.24–2.23)

0.8%

Bentall

Pooled Late Outcome Events	LOR + 95% CI
Late mortality ^a	2.02 (1.77–2.31)
Valve-related mortality	0.46 (0.36–0.59)
Root reoperation ^b	0.46 (0.36–0.59)
Valve reoperation	0.30 (0.22–0.41)
Hemorrhage	0.64 (0.47–0.87)
Thromboembolism	0.77 (0.60–1.00)
Endocarditis	0.39 (0.33–0.46)
MAVRE	2.66 (2.17–3.24)

B. Arabkhani, JJ. Takkenberg ATS 2015
A. Mookhoek, JJ. Takkenberg ATS 2016

VSRR: Why we do it?

Why do a Valve-Sparing Reimplantation Procedure?

1. SAFE
2. Durable
3. Excellent Long-Term Survival
4. Low VRE

General Principles


1. Restore and preserve cusp geometry and motion

+




2. Remodel and stabilize the FAA




Optimal area of coaptation, stable over time



Optimal Coaptation




Schafers H.J. JCTVS 2006
Bierbach B.O., EJCTS 2010
Aicher D. Circ. 2011



Optimal Coaptation & Stabilisation

- Effective height (eH) \geq 9 mm
- Coaptation length \geq 4 mm
- Circumferential annuloplasty VAJ $>$ 26
- No residual AR




Pethig K. ATS 2002
le Polain de Waroux JB. JACC Card. Im. 2009
Bierbach BO. EJCTS 2010
Aicher D. Circ. 2011
De Kerchove L. JTCVS 2011

Evolution of the Remodeling technique



Partial
external band



T. David 1996

Circumferential
external band



E. Lansac 2006


Suture
Annuloplasty




HJ. Schäfers 2013

Evolution of the Reimplantation technique

Reimplantation



Stanford Modification



C. Miller

Valsalva®



R. De Paulis 2002

Sinus Graft




Cardioroot®




*Uni-Graft®
Sinus*

Deep External Root dissection for VSR or External Ring

TAV





BAV



Brussels AV repair: *Why is VSR so efficient?*




1. Circumferential prosthetic annuloplasty → **Stable over time**



Brussels AV repair: ***Why is VSR so efficient?***



1. Circumferential prosthetic annuloplasty  **Stable over time**
2. Remodel BAV geometry to 180°
3. Optimal Coaptation

"Assymmetric annuloplasty"





Brussels' BAV repair: *Why is VSR so efficient?*

1. Circumferential prosthetic annuloplasty → **Stable over time**
2. Remodel BAV geometry to 180° → **Durable configuration**
3. Optimal Coaptation → **Reduce the need of patch**




Brussels' BAV repair: *Why is VSR so efficient?*

1. Circumferential prosthetic annuloplasty → **Stable over time**
2. Remodel BAV geometry to 180° → **Durable configuration**
3. Optimal Coaptation → **Reduce the need of patch**



Pethig K. ATS 2002



le Polain JB. JACC Card. Im. 2009






Aicher D. Circ. 2011


VSRR was developed to treat aortic root aneurism in TAV !

Root aneurism/no AI



Root aneurism + AI





Adult Echo

X8-2t

53Hz

9.0cm

Z 1.1

2D

48%

C 50

P Off

HGen




TIS0.2 MI 0.6

M4



G
P R
2.7 5.4

PAT T: 37.0C
TEE T: 38.5C



47 bpm

VSRR: *Why Reimplantation should be preferred*

- Reimplantation techniques:
 - ✓ Safe and reproducible, disseminated worldwide
 - ✓ Proven long term durability in TAV, BAV, Marfan, dissection and in AI !
 - ✓ One sizing, one device (graft)
 - ✓ Ability to modify valve geometry (\rightarrow 180°symmetric configuration)
- Remodeling alone ok if no CTD, no or few central AI, no annulus dilatation !

VSRR: Whatever the technique you choose, *do a Reimplantation !*



Brussels Gallic's
Technique



Homburg Gallic's
technique



Paris Gallic's
technique



Highly selected population

Results of aortic valve-sparing operations

Tirone E. David, Susan Armstrong, Joan Ivanov, Christopher M. Feindel, Ahmad Omran
and Gary Webb

J Thorac Cardiovasc Surg 2001;122:39-46

- 120 patients
- Reimplantation 53%
- Remodeling 47%
- Marfan 45%
- BAV 2%
- AI 3+ 4+ 40%
- Cusp repair 11%












Figure 3. Freedom from 3+ or 4+ AI.



Analysis of the mechanisms of failure



Valve sparing technique ? Need for cusp repair ?

Functional Classification of AI

AI Class	Type I Normal cusp motion with FAA dilatation or cusp perforation				Type II Cusp Prolapse	Type III Cusp Restriction
	Ia	Ib	Ic	Id		
Mechanism						
Repair Techniques (Primary)	STJ remodeling <i>Ascending aortic graft</i>	Aortic Valve sparing: <i>Reimplantation or Remodeling with SCA</i>	SCA	Patch Repair <i>Autologous or bovine pericardium</i>	Prolapse Repair <i>Plication Triangular resection Free margin Resuspension Patch</i>	Leaflet Repair <i>Shaving Decalcification Patch</i>


+ Annuloplasty

El Khoury G.
Cur. Op. Card. 2005

AI and leaflet repair in valve sparing reimplantation


Effects of Preoperative Aortic Insufficiency on Outcome After Aortic Valve–Sparing Surgery

- 164 patients
- Reimplantation 75%
- Remodeling 25%
- Marfan 10%
- BAV 32%
- AI 3+ 4+ 60%
- Cusp repair 55%




Probability of Cusp Repair in VSRR in function of preoperative AI

- No AI




➤ Low ± 10%

- Central AI




➤ Moderate ± 50%

- Eccentric AI




➤ High ± 100%

Cusp configuration in AV repair





Cusp Repair is crucial to achieve good valve configuration!

Cusp configuration in AV repair




G. El Khoury G.




Aicher D. Circ. 2011

But AI was NOT the ONLY problem in VSRR

Remodeling



Reimplantation




- *Birks EJ., Yacoub MH. Circulation. 1999*
- *De Olievera NC., David TE. JTCVS 2003*
- *Miller DG. JTCVS 2003*
- *Bethea BT., Cameron D. ATS 2004*
- *David T. JTCVS 2006*
- *Erasmi A., Sievers HH. ATS 2007*

} Suggest better repair durability with the Reimplantation technique

Annulus dilatation is very bad in remodeling

Remodeling



✓ Hanke T., Sievers H.J. JTCVS 2009:

- 191 VSRR, 76% TAV
- 56% Remodeling

✓ Kunihara T., Schäfers H.J. JTCVS 2012:

- 430 VSRR, 70% TAV,
- 93% remodeling

✓ Schäfers H.J. JTCVS 2016:

- 747 Remodeling, 58% TAV,




TABLE 2. Risk factors by multivariate Cox regression analysis ($-2 \log\text{-likelihood function} = 161.87$, chi-square = 72.79, $P < .001$)

Variable	P value	HR	95% CI
Diameter of AV junction (mm)	<.001	1.43	1.21-1.69
Use of annuloplasty	.01	1.28	1.89-66.26
Myocardial ischemia (min)	.04	0.96	0.93-1.00
Effective height	<.001	0.58	0.43-0.79
Use of pericardial patch	<.001	6.24	2.30-16.90

AV, Aortoventricular; CI, confidence interval; HR, hazard ratio.

Relationship between chronic AI and annulus dilatation


- 127 pts with chronic AR, 74% TAV, 16% BAV

Table II. Degree of AR and aortic root size indexed by body surface area at follow-up study


	Mild AR (cm/m ²) (n = 67)	Moderate AR (cm/m ²) (n = 45)	Severe AR (cm/m ²) (n = 15)	p Value*
Aortic annulus	1.29 ± 0.23	1.38 ± 0.23	1.39 ± 0.11	0.055
Valsalva sinuses	1.89 ± 0.34	2.04 ± 0.31	2.09 ± 0.32	0.025
Supraaortic ridge	1.49 ± 0.30	1.71 ± 0.35	1.76 ± 0.43	0.001
Ascending aorta	1.97 ± 0.42	2.16 ± 0.49	2.19 ± 0.47	0.049

Padial LR. Am. Heart. J. 1997

- 84 pts BAV with AR




Keane M.G. Circulation. 2000




VAJ dilatation



Normal VAJ



Dilated VAJ



Annulus size in normal and pathological settings



Ratio 0,8

	Normal TAV N=32	AI or aneurism TAV N=37	AI or aneurism BAV N= 27
2D echo	22.8 ± 2.4	26.1 ± 4.1&	30 ± 3.9&\$
3D small Ø	21.8 ± 2.5	25.1 ± 4.7&	28.1 ± 3.5&\$
3D long Ø	26.9 ± 2.2	27.6 ± 4.9	30.8 ± 4&\$
Small/long ratio	0.8 ± 0.1	0.9 ± 0.1&	0.9 ± 0.1&

* p < 0.05 vs normal TAV; & p < 0.001 vs normal TAV; \$ p < 0.001 vs repaired TAV

	AI or aneurism TAV		AI or aneurism BAV	
	AI ≤ 1	AI ≥ 2	AI ≤ 1	AI ≥ 2
2D echo	23.4 ± 2.5	27.2 ± 3.9*	26.6 ± 2.6*	31.3 ± 3.8\$&
3D small Ø	22.5 ± 3.4	26.1 ± 4.5*	25.3 ± 2.4	29.2 ± 3.3\$&
3D long Ø	25.4 ± 3.8	28.3 ± 4.8	27.8 ± 1.7	32.1 ± 4.3\$&
Small/long ratio	0.9 ± 0.1	0.9 ± 0.1	0.9 ± 0.1	0.9 ± 0.1

* p < 0.05 vs TAV without AR; \$ p < 0.05 vs TAV with significant AR; & p < 0.05 vs BAV without AR

VAJ size in normal and pathological settings

	AI or Ao aneurism TAV (mm)	AI or Ao aneurism BAV (mm)
<i>Navarra E. EJCTS 2013</i>	-	28 mm(2D echo)
<i>de Kerchove L. EJCTS 2015</i>	25.2mm (2D echo)	-
<i>Lansac E. EJCTS 2016</i>	(2/3 TAV, 1/3 BAV) 28.3 mm (Hegar dilator)	
<i>Schäfers H.J. JTCS 2013</i>	27.6 (2D echo) 30.2 (Hegar dilator)	29.7(2D echo) 31.8 (Hegar dilator)

→ 2D echo measure ≈ Hegar dilator measures +2-3 mm

Role of VAJ size and annuloplasty in AV repair


- VSR technique

BAV

(Hospit. mortality: 0%)



FF AR >1+



Navarra E. EJCTS 2013


TAV

(Hospit. mortality: 0.6%)



FF AR >1+

p = 0.4




De Kerchove L. EJCTS 2015

Role of VAJ size and annuloplasty in AV repair


- SCA versus VSR technique (matched groups)

BAV




De Kerchove L. JTCS 2010

TAV




De Kerchove L. EJCTS 2015

VAJ dilatation occurs in most patients with SCA in TAV repair






Brussels AV repair: ***Why is VSR so efficient?***

1. Circumferential prosthetic annuloplasty → **Stable over time**
2. Remodel BAV geometry to 180° → **Durable configuration**
3. Optimal Coaptation



D. Aicher Circ. 2011

Rate of VS Reimplantation over year at St-Luc, Brussels



FIFTEEN-YEAR EXPERIENCE WITH VALVE SPARING – REIMPLANTATION TECHNIQUE FOR THE TREATMENT OF AORTIC ANEURYSM AND AORTIC REGURGITATION

**Mastrobuoni S. MD MPH, de Kerchove L. MD PhD, Navarra E. MD, Astarci P. MD
PhD, Poncelet A. MD PhD, Rubay J. MD, Noirhomme P. MD, El Khoury G. MD**

Departement of Cardiothoracic and Vascular Surgery
Cliniques Universitaires St-Luc, IREC, UCL, Brussels, Belgium



Materials and Methods


- Between 1999-2017, 923 patients underwent AV repair at St. Luc's Hospital;
- **440 patients (47.7%)** were treated with VSRR and are the Study Cohort;
- Patients were divided into **3 groups** according to the indication for surgery:
 - Root aneurysm without AR (**Conventional Indication**)
Group 1 = 139 patients (31.6%)
 - Root aneurysm with significant AR (“**debated” indication**)
Group 2 = 212 patients (48.2%)
 - Isolated AR (**non-conventional indication**)
Group 3 = 76 patients (17.3%)
- Further 13 patients (2.7%) presented with acute type-A aortic dissection

Results: Freedom from AV reop by Group

4 in Group Aneurysm (3%)

9 in Group Aneurysm+AR (4.4%)


4 in Group isolated AR (5.9%)



89.6% (95% CI: 82.2-94.0) at 10-year

Results: Freedom from AV reop by valve phenotype

4 in BAV (2.4%)
13 in TAV (5.1%)




Freedom from recurrent severe AR (≥ 3) by Group

3 in Group Aneurysm (2.4%)

7 in Group Aneurysm + AR
(3.6%)

4 in Group isolated AR (5.9%)




Number at risk

Group = Aneurysm + AR	192	99	30	2
Group = Aneurysm	125	55	12	2
Group = isolated AI	65	19	3	1

- Group = Aneurysm + AR
- Group = Aneurysm
- Group = isolated AI

Brussels approach of root repair in regurgitant BAV



Thank you

Indications for VAJ annuloplasty

Aortic valve repair for AI

Normal Root (<45 mm)

Dilated Root (≥ 45 mm)

Normal VAJ
(<26 mm)


Large VAJ
(>26 mm)

- Large VAJ (> 28 mm)
- Root wall disease, +>40 mm
- Modify valve geometry (BAV)

No Annuloplasty

Ring annuloplasty

a **Exception:**
- small VAJ/cusp
- Endocarditis
- Old patient
- VAJ 26-28




(>26 mm)

(<26 mm)


Reimplantation



Remod.+ Anpl



Remodeling



Demographics


	Aneurysm n=139	Aneurysm + AR n=212	Isolated AR n=76	p
Mean age \pm SD (years)	47 \pm 14	51 \pm 15	42 \pm 13	0.05
Male, n (%)	128 (92.1)	191 (90.1)	70 (92.1)	0.7
Bicuspid AV, n (%)	49 (35.2)	76 (55.9)	52 (68.4)	<0.001
Grade of Aortic regurgitation, n (%)				
0-1	139 (100)	0	0	
2		70 (33.0)	6 (7.9)	
3		103 (48.6)	58 (76.3)	
4		39 (18.4)	12 (15.8)	
NYHA Functional Class (%):				
I	112 (80.6)	105 (93.7)	41 (53.9)	
II	23 (16.5)	79 (37.3)	30 (39.5)	
III	3 (2.2)	28 (13.2)	5 (6.6)	
IV	1 (0.7)	0	0	
LV Ejection Fraction				
\geq 50%	132 (95)	175 (82.5)	69 (90.8)	
31-49	7 (5)	33 (15.6)	7 (9.2)	
\leq 30	0	4 (1.9)	0	
LVEDD (mm), mean \pm SD	53 \pm 5	61 \pm 8	63 \pm 7	0.02
VAJ (mm), mean \pm SD	27 \pm 3*	28 \pm 4	29 \pm 4*	0.007*
Previous Ross operation, n (%)	3 (2.1)	4 (1.9)	5 (6.6)	0.09
Connective Tissue Disorder, n (%)	19 (13.7)	14 (6.6)	1 (1.3)	0.004

Results: intra- and post-op data

	Aneurysm n=139	Aneurysm + AR n=212	Isolated AR n=76	<i>p</i>
Graft size mm, median	30	30	30	0.3
CPB Time (min) mean \pm SD	145 \pm 35	150 \pm 34	151 \pm 26	0.6
Concomitant Procedures, n(%):				
Mitral Valve Repair	37 (26.6)	54 (25.5)	13 (17.1)	0.2
Hemi-arch	5 (5.0)	13 (6.1)	6 (7.9)	
CABG	4 (2.9)	12 (5.6)	0	
CABG	18 (0.7)	9 (4.2)	4 (5.2)	
Cusp Repair	76 (54.7)	170 (80.2)	74 (97.4)	<0.001
Patch	1 (0.7)	15 (7.1)	4 (5.2)	0.02
Re-exploration fro bleeding, n (%)	21 (15.1)	23 (10.9)	8 (10.5)	0.4
Permanent Pacemaker Insertion, n (%)	9 (6.5)	7 (3.3)	5 (6.6)	0.3
30-days death	1 (0.7)	0	0	0.3
Lost to Follow-up, n(%)	4 (2.9)	8 (3.8)	10 (13.1)	0.002
Follow-up years, Median (IQR)	4.7 (2-8.5)	5.5 (2.2-9.7)	3.5 (1.7-5.8)	

Results: Long-term survival by Group

34 late deaths (10 cardiac related)
22 in Group Aneurysm (16.5%)
11 in Group Aneurysm + AR (5.8%)
1 in Group isolated AR (1.5%)



Mortality rate: 1.5% patient-year [Bentall: 2.02%]
Alive: 81.3% (95% CI: 72.9-87.3) at 10-year